Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04513639Phase 2Recruiting

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Role: collaborator

NCT03730220Completed

The Norwegian Induction Project: a Pilot for a Prospective National Audit

Role: collaborator

NCT01482104Not ApplicableCompleted

New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)

Role: collaborator

All 3 trials loaded